Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

TitlePreexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.
Publication TypeJournal Article
Year of Publication2012
AuthorsStephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH
JournalJ Infect Dis
Volume205
Issue12
Pagination1806-10
Date Published2012 Jun 15
ISSN1537-6613
KeywordsAdenovirus Infections, Human, Adenoviruses, Human, Adult, Antibodies, Viral, Case-Control Studies, Clinical Trials as Topic, Female, HIV Infections, HIV-1, Humans, Male
Abstract

The Step study of a recombinant adenovirus serotype 5 (Ad5)-based human immunodeficiency virus type 1 (HIV-1) vaccine revealed an increased risk of HIV-1 acquisition in vaccinees who were Ad5 seropositive at baseline. We therefore investigated whether preexisting Ad seropositivity to 7 different Ad serotypes was associated with increased risk of HIV-1 infection in 3 HIV-1 vaccine efficacy trials. In a case-control study involving 1570 adults enrolled in the VAX003 and VAX004 trials of a recombinant protein subunit HIV-1 vaccine and in the Step study, we observed that preexisting seropositivity to multiple Ad serotypes was not intrinsically associated with increased risk of HIV-1 acquisition.

DOI10.1093/infdis/jis285
Alternate JournalJ. Infect. Dis.
PubMed ID22492863